Literature DB >> 12225364

The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization.

Maria E Baca-Estrada1, Catherine Ewen, Donna Mahony, Lorne A Babiuk, Darryl Wilkie, Marianna Foldvari.   

Abstract

Topical application of antigen induces antigen-specific humoral and cellular immune responses. In this study we examined whether expansion of dendritic cells (DC) by Flt3 ligand (Flt3L) treatment influences the induction of immune responses following transcutaneous immunization. Mice were treated intraperitoneally with Flt3L or phosphate-buffered saline (PBS) and immunized transcutaneously with hen egg lysozyme (HEL). Flt3L-treated mice developed lower HEL-specific cellular and humoral immune responses than PBS-treated mice. However, in the presence of cholera toxin (CT), a potent adjuvant for mucosal and transcutaneous immunization, Flt3L-treated mice developed significantly higher cellular and humoral immune responses to HEL when compared to PBS-treated mice. We assessed whether the immunomodulatory effects of CT were a result of activation of epidermal dendritic cells (Langerhans' cells; LC). Our results indicate that within 8-12 hr of topical application of CT, epidermal LC cells lose their dendritic morphology and become rounder in appearance. In addition, we observed enhanced expression of major histocompatibility complex (MHC) class II, and of adhesion molecules CD11c and intracellular adhesion molecule-1 (ICAM-1). Our observations support the concept that the state of activation of DC in the skin is central to the regulation of immune responses. This information is relevant to the design of effective transcutaneous vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225364      PMCID: PMC1782769          DOI: 10.1046/j.1365-2567.2002.01488.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

Review 1.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming.

Authors:  M C Gagliardi; F Sallusto; M Marinaro; A Langenkamp; A Lanzavecchia; M T De Magistris
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

3.  CpG motifs induce Langerhans cell migration in vivo.

Authors:  E Ban; L Dupré; E Hermann; W Rohn; C Vendeville; B Quatannens; P Ricciardi-Castagnoli; A Capron; G Riveau
Journal:  Int Immunol       Date:  2000-06       Impact factor: 4.823

4.  Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand.

Authors:  C Esche; V M Subbotin; O Hunter; J M Peron; C Maliszewski; M T Lotze; M R Shurin
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

5.  Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro.

Authors:  A Bromander; J Holmgren; N Lycke
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

6.  Phenotypic and functional characteristics of in vivo-activated Langerhans cells.

Authors:  S Aiba; S I Katz
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

7.  Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice.

Authors:  L F Wang; J Y Lin; K H Hsieh; R H Lin
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

8.  55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression.

Authors:  U Trefzer; M Brockhaus; H Loetscher; F Parlow; A Kapp; E Schöpf; J Krutmann
Journal:  J Invest Dermatol       Date:  1991-11       Impact factor: 8.551

9.  Antigen-bearing langerhans cells in skin, dermal lymphatics and in lymph nodes.

Authors:  I Silberberg-Sinakin; G J Thorbecke; R L Baer; S A Rosenthal; V Berezowsky
Journal:  Cell Immunol       Date:  1976-08       Impact factor: 4.868

Review 10.  Relation between langerhans cells, veiled cells, and interdigitating cells.

Authors:  E C Hoefsmit; A M Duijvestijn; E W Kamperdijk
Journal:  Immunobiology       Date:  1982-04       Impact factor: 3.144

View more
  6 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

Review 3.  Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.

Authors:  Kosuke Kataoka; Yoshiko Fukuyama; David E Briles; Tatsuro Miyake; Kohtaro Fujihashi
Journal:  Microbiol Immunol       Date:  2017-06       Impact factor: 1.955

4.  Use of genetic immunization to generate a high-level antibody against rat dicarboxylate transporter.

Authors:  Guoshuang Xu; An Liu; Xiaowei Liu
Journal:  Int Urol Nephrol       Date:  2008-08-09       Impact factor: 2.370

5.  A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.

Authors:  Shinichi Sekine; Kosuke Kataoka; Yoshiko Fukuyama; Yasuo Adachi; Julia Davydova; Masato Yamamoto; Ryoki Kobayashi; Keiko Fujihashi; Hideaki Suzuki; David T Curiel; Satoshi Shizukuishi; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 6.  Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.

Authors:  Kosuke Kataoka; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.